Stephen G. Machatha
2022
In 2022, Stephen G. Machatha earned a total compensation of $2.6M as Chief Development Officer at Aldeyra Therapeutics, a 79% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $208,086 |
|---|---|
| Option Awards | $818,523 |
| Salary | $359,287 |
| Stock Awards | $1,167,121 |
| Other | $12,200 |
| Total | $2,565,216 |
Machatha received $1.2M in stock awards, accounting for 45% of the total pay in 2022.
Machatha also received $208.1K in non-equity incentive plan, $818.5K in option awards, $359.3K in salary and $12.2K in other compensation.
Rankings
In 2022, Stephen G. Machatha's compensation ranked 1,417th out of 5,760 executives tracked by ExecPay. In other words, Machatha earned more than 75.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,417 out of 5,760 | 75th |
Division Manufacturing | 705 out of 3,136 | 78th |
Major group Chemicals And Allied Products | 269 out of 1,422 | 81st |
Industry group Drugs | 248 out of 1,323 | 81st |
Industry Pharmaceutical Preparations | 175 out of 969 | 82nd |
Source: SEC filing on May 23, 2023.
Machatha's colleagues
We found two more compensation records of executives who worked with Stephen G. Machatha at Aldeyra Therapeutics in 2022.